Surrozen, Inc. (SRZN)
19.96
-0.72
(-3.48%)
USD |
NASDAQ |
Sep 09, 16:00
19.96
0.00 (0.00%)
After-Hours: 16:07
Surrozen Shareholders Equity (Quarterly) : -218.66M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -218.66M |
| March 31, 2026 | -278.15M |
| December 31, 2025 | -187.76M |
| September 30, 2025 | -23.52M |
| June 30, 2025 | 47.11M |
| March 31, 2025 | 5.674M |
| December 31, 2024 | -21.38M |
| September 30, 2024 | 5.667M |
| June 30, 2024 | 6.062M |
| March 31, 2024 | 30.14M |
| December 31, 2023 | 37.94M |
| September 30, 2023 | 45.53M |
| Date | Value |
|---|---|
| June 30, 2023 | 55.06M |
| March 31, 2023 | 63.04M |
| December 31, 2022 | 76.00M |
| September 30, 2022 | 77.49M |
| June 30, 2022 | 89.70M |
| March 31, 2022 | 102.66M |
| December 31, 2021 | 109.70M |
| September 30, 2021 | 123.73M |
| June 30, 2021 | 83.04M |
| March 31, 2021 | 86.63M |
| December 31, 2020 | 47.29M |
| September 30, 2020 | 0.02M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 115.61M |
| Total Liabilities (Quarterly) | 334.27M |
| Debt to Equity Ratio | -0.0289 |
| Current Ratio | 12.14 |
| Net Debt Paydown Yield | 0.11% |